Status:
COMPLETED
A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
This study was not conducted in the United States. Many people with type 2 diabetes also have high cholesterol levels. The purpose of this study was to evaluate the effects of vildagliptin, an unappro...
Eligibility Criteria
Inclusion
- Blood glucose criteria must be met
- Genetic markers associated with increased risk of cardiovascular disease
- Not currently on drug therapy for type 2 diabetes
- Body mass index (BMI) in the range 25-40
Exclusion
- Pregnancy or lactation
- Type 1 diabetes
- High cholesterol as defined by the protocol
- Evidence of serious diabetic complications
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00099957
Start Date
September 1 2003
End Date
June 1 2005
Last Update
May 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland